Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
Research in the Drake Lab focuses on blending basic and translational research approaches to better understand the signaling networks in lethal metastatic castration resistant prostate cancer, and how to more effectively treat patients who are suffering from this disease using rationalized targeted therapies. Previous research from Dr. Drake and others suggest that kinase activation may be a primary mechanism of resistance to current therapies in late stage prostate cancer. Using in vivo primary mouse and human cancer model systems, the Drake Lab investigates what particular kinase signaling pathways are activated that lead to this resistance and how new targeted therapies, such as kinase inhibitors, may perturb these pathways for future clinical utility.
In addition and in collaboration with the Rutgers University Center for Integrative Proteomics Research, Dr. Drake’s lab will also employ phosphoproteomics enrichment technologies coupled to quantitative targeted mass spectrometry to identify the activated kinases and pathways in clinical tumors for development of predictive biomarkers. The results of this research aim to evaluate single biopsies from metastatic prostate cancer tissues for activated kinase signatures that will lead to targeted therapies in real time. This research is currently supported by the Department of Defense Prostate Cancer Research Program.
The Drake Lab is supported by the following grants: